Company intelligence / Profile preview
AIM Vaccine Co., Ltd.
Beijing, Beijing, Chinaaimbio.com ↗
- Ownership
- Private
- Employees
- ~1535
- Development stage
- Commercial
01
Overview
AIM Vaccine has 8 commercialized vaccines for 6 disease fields and 21-23 innovative vaccines under development for 13 disease fields. The company recently completed Phase III trials for a rabies vaccine and submitted a marketing registration application.
- Therapeutic areas
- Infectious Diseases
- Modalities
- VaccinesmRNA vaccinesRecombinant vaccinesInactivated vaccinesLive attenuated vaccinesConjugate vaccinesPolysaccharide vaccines
- Industry
- Biotech
02
Drug pipeline
47 assets46 more assets in the full pipeline.
Beyond the preview
Go deeper on AIM Vaccine Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AIM Vaccine Co., Ltd..